EHS
EHS

STAT Plus: Pharmalittle: California transparency law stalls some price hikes; Pfizer reorganizes operations, again

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …

A handful of big drug makers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs, Bloomberg News reports. The law requires drug makers to give insurers, governments, and purchasers advance notice of large price hikes. In the past three weeks, Novartis (NVS), Gilead Sciences (GILD), Roche (RHHBY), and Novo Nordisk (NVO) sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.

Continue to STAT Plus to read the full story…

EHS

Leave a Reply

Your email address will not be published.

Back to top button